Intelligence · Clinical Development
Pipeline search results
Programs matching “neratinib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 27 pipeline programs matching "neratinib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Trastuzumab and neratinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early-stage Breast Cancer
1 trial -
neratinib
PUMA BIOTECHNOLOGY, INC.
HER2+ Metastatic Breast Cancer (MBC)
1 trial -
NERATINIB
PUMA BIOTECHNOLOGY, INC.
Stage IV (Metastatic) Breast Cancer
1 trial -
NERATINIB, Sindiar 2 mg cápsulas duras
Ningbo Cancer Hospital
HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Breast Cancer.
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Advanced Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Breast Cancer
8 trials -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Early-stage Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Triple Negative Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Anatomic Stage I Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Early Stage HER2+ Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
GastroEsophageal Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
HER2 Amplified Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
HER2-positive Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Metastatic Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Metastatic Prostate Adenocarcinoma
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Solid Tumor, Adult
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
1 trial -
neratinib
PUMA BIOTECHNOLOGY, INC.
HER2-mutant Non-Small Cell Lung Cancer
1 trial -
neratinib
PUMA BIOTECHNOLOGY, INC.
Breast Neoplasms
3 trials -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Neoplasms
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Healthy Subjects
3 trials -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Advanced Malignant Solid Tumors
3 trials -
Neratinib (HKI-272)
PUMA BIOTECHNOLOGY, INC.
Hepatic Insufficiency
1 trial -
Neratinib 160 mg
PUMA BIOTECHNOLOGY, INC.
Advanced Solid Tumor
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.